AgentFlare

Markets · Health Care · JNJ · NYSE

Johnson & Johnson (JNJ) trades at $253.47, below its $278.43 six-month high

Johnson & Johnson shares last traded at $253.47, down 0.17% on the day, after a six-month high of $278.43 on 2026-09-03. Recent headlines cover a MedTech spinoff target and an investor investigation notice.

Price$253.47-0.17%
1 month+8.09%
6 months+15.96%
Market cap$610.84B
P/E29.40
Net margin21.5%
JNJ — 6-month daily close2026-04-14 → 2026-09-03 · AISA Financial API
JNJ daily close: 04-14 $240.10 → 09-03 $278.43; high $278.43 (09-03), low $221.32 (05-08)$216.75$238.83$260.92$283.0004-1406-2409-03
402 · Pay-per-Crawl$0.01

You're reading the full report — free for humans and search engines. The same content ships as a structured JSON dataset (normalized facts, sources and citation arrays, no HTML parsing) so AI agents can consume it directly — metered per fetch via the open HTTP 402 payment protocol.

⚡ Agents: fetch .data.json · $0.01 → agents: crawlerAutoPrice=true · verify at https://esa.aisa.one/api/v1/access/verify

What the company does

Johnson & Johnson (JNJ) operates in the Health Care sector, within the Pharmaceuticals industry, and is based in New Jersey, U.S.A. Its shares trade on the NYSE with a market capitalization of $610.84B. Latest-period revenue grew 8.1% year over year, and the company reported a gross margin of 67.9% and an operating margin of 26.7%. Recent headlines also refer to its MedTech operations.

Price action and valuation versus peers

The last price is $253.47, down 0.17% on the day. The stock is up 8.1% over about one month, 22.0% over about three months and 16.0% over about six months. The six-month high was $278.43 on 2026-09-03, and the low was $221.32 on 2026-05-08. At a P/E of 29.40, the stock sits below the tracked Health Care peer median P/E of 41.87, based on UNH and LLY. Its P/S is 6.24 and EV/EBITDA is 18.87.

What the recent headlines say

Trefis (2026-10-14) asked what the open question is under the share price. Simply Wall Street reported that the stock dropped and asked what was behind the latest attention. MassDevice reported that Johnson & Johnson MedTech set a mid-2027 target for its ortho spinoff, as Q3 device sales disappointed. Johnson & Johnson said ICOTYDE® was named to Time's Best Inventions of 2026. A PR Newswire notice from SueWallSt said it notified investors of a pending investigation into JNJ.

Fundamentals

P/E vs Health Care peersTracked peers in the same sector · ▶ this stock
price-to-earnings: LLY 41.9, ▶ JNJ 29.4, UNH 26.1LLY41.9▶ JNJ29.4UNH26.1
Margins & returnsLatest reported period
margins: Gross 67.9%, Operating 26.7%, Net 21.5%, ROE 24.8%Gross67.9%Operating26.7%Net21.5%ROE24.8%
Growth, year over yearLatest reported period
growth: Revenue +8.06%, Earnings -7.17%, Free cash flow +19.92%, EPS -7.97%Revenue+8.06%Earnings-7.17%Free cash flow+19.92%EPS-7.97%
Market cap$610.84BEnterprise value$639.45B
P/E29.40P/S6.24
P/B7.19EV/EBITDA18.87
PEG-3.69EPS$8.62
Debt/equity0.58Current ratio1.09
FCF yield3.6%Payout ratio60.0%

Recent headlines

In the AgentFlare Newswire

What to watch

  • Mid-2027 target for the ortho spinoff, per MassDevice
  • Pending investigation notice from SueWallSt, per PR Newswire
  • Q3 device sales disappointment, per MassDevice

FAQ

What is the latest price and recent move?

The last price is $253.47, down 0.17% on the day. The stock is up 8.1% over about one month and 16.0% over about six months, with a six-month high of $278.43 on 2026-09-03.

How does the valuation compare with peers?

The P/E is 29.40 against a tracked Health Care peer median P/E of 41.87, based on UNH and LLY. The P/B is 7.19 and the debt/equity ratio is 0.58.

What did the recent headlines report?

MassDevice reported a mid-2027 target for the ortho spinoff as Q3 device sales disappointed. Simply Wall Street reported the stock dropped. A PR Newswire notice said SueWallSt notified investors of a pending investigation.

How this page is made. Prices, fundamentals and headlines come from the AISA Financial API; peers are the other tracked stocks in the same sector. The profile is written by a language model from those numbers and headlines only — figures not in the data are removed. Nothing here is investment advice.

Sources & citations

  1. J&J's ICOTYDE® Named to Time's Best Inventions of 2026 - Johnson & Johnson Johnson & Johnson · 2026-10-15
  2. Johnson & Johnson Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Johnson & Johnson (JNJ) - PR Newswire PR Newswire · 2026-10-14
  3. The Open Question Under Johnson & Johnson Stock’s Price - Trefis Trefis · 2026-10-14
  4. Johnson & Johnson (JNJ) Stock Dropped, What Is Behind The Latest Attention? - Simply Wall Street Simply Wall Street · 2026-10-14
  5. Johnson & Johnson (JNJ) Stock Dropped, What Is Behind The Latest Attention? - Simply Wall Street Simply Wall Street · 2026-10-14
  6. AISA Financial API
  7. Johnson & Johnson SEC filings

Related